Tilak Gains CE Marking for Odysight, a Mobile Medical Game for Chronic Eye Disease

June 29, 2018: By Jon Swedien

Tilak has gained CE marking for Odysight, the company’s mobile medical game for monitoring patients with chronic eye disease, the Paris-based firm announced June 14.

The puzzle game for smartphones and tablets monitors the evolution of visual parameters—near visual acuity, contrast sensitivity, and the presence and evolution of scotomas or metamorphosis—and triggers regular medical tests for patient follow-up.

In-house doctors and video game professionals worked together to create the game, which includes elements of a modern mobile video game—artistic direction, simple game mechanics, and a level of difficulty adapted to the patient.

Odysight is available on Apple’s App Store and the Google Play store by medical prescription.

Tilak was founded in May 2016 and is part of the iBionext network. iBionext has helped create eight companies, including Pixium Vision and GenSight Biologics, the management company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023